AMPLYX PHARMACEUTICALS
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.
AMPLYX PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Medical Pharmaceutical
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.amplyx.com
Total Employee:
11+
Status:
Active
Contact:
+118583484458
Email Addresses:
[email protected]
Total Funding:
198.37 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Oracle Cloud Proofpoint
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Pappas Capital
Pappas Capital investment in Series C - Amplyx Pharmaceuticals
Adage Capital Management
Adage Capital Management investment in Series C - Amplyx Pharmaceuticals
Arix Bioscience
Arix Bioscience investment in Series C - Amplyx Pharmaceuticals
Pfizer
Pfizer investment in Series C - Amplyx Pharmaceuticals
BioMed Ventures
BioMed Ventures investment in Series C - Amplyx Pharmaceuticals
RiverVest
RiverVest investment in Series C - Amplyx Pharmaceuticals
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - Amplyx Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series C - Amplyx Pharmaceuticals
3×5 Partners
3×5 Partners investment in Series C - Amplyx Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series C - Amplyx Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2020-06-08 | Amplyx Pharmaceuticals Expands Executive Leadership Team |
| 2020-02-04 | Amylyx Pharmaceuticals Appoints Jeffrey Trigilio Chief Financial Officer |
Official Site Inspections
http://www.amplyx.com
- Host name: 147.154.27.36
- IP address: 147.154.27.36
- Location: Seattle United States
- Latitude: 47.6109
- Longitude: -122.3303
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98101
More informations about "Amplyx Pharmaceuticals"
Leadership Team - Amylyx
Progress is made possible thanks to the passion and drive of every Amylyx team member, and we promise to strive to always be true partners to the people and communities affected by these …See details»
Amylyx Pharmaceuticals - Wikipedia
Amylyx Pharmaceuticals was founded in 2013 by Joshua Cohen and Justin Klee when the two were undergraduate students at Brown University. The two proposed that taurursodiol and sodium phenylbutyrate together might prevent dysfunction of mitochondria and the endoplasmic reticulum, safeguarding neurons. Klee and Cohen were advised by Rudolph E. Tanzi, who ultimately served as the founding chair of Amylyx's scientific research board. After Klee and Cohen were able to a…See details»
Amylyx Pharmaceuticals - Crunchbase Company Profile …
Organization. Amylyx Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Amylyx Pharmaceuticals reported robust revenue growth and net income for …See details»
Amylyx Pharmaceuticals - LinkedIn
Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work ...See details»
Investors | Amylyx Pharmaceuticals, Inc.
Oct 15, 2024 At Amylyx, our moments are spent in the pursuit of furthering treatment options for those living with neurodegenerative diseases. Every day presents an opportunity to turn these …See details»
Amylyx Pharmaceuticals - Overview, News & Similar companies
May 9, 2024 Who is Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis …See details»
Amylyx Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Amylyx has 3 employees across 8 locations and $380.79 m in annual revenue in FY 2023. See insights on Amylyx including office locations, competitors, revenue, financials, …See details»
Why Amylyx is pulling ALS drug Relyvrio from US …
Apr 4, 2024 The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the …See details»
AMLX.O - | Stock Price & Latest News | Reuters
Jun 21, 2024 Amylyx Pharmaceuticals Inc AMLX.O. Official Data Partner. Latest Trade. trading higher 5.27 USD. Change 0.08 % Change + 1.54% Positive As of Nov 24, 2024. Values …See details»
News - Amylyx
Get the latest news and updates from Amylyx, delivered right to your inbox. For investors, please click here for email alerts. * indicates required. First Name * Last Name * Email * I am a(n) (Select all that apply)* Person living with …See details»
Amylyx Pharmaceuticals Announces Formal Intention to Remove …
Which will allow the organization to deliver on key upcoming milestones, including data readouts from HELIOS (AMX0035 in Wolfram syndrome), ORION (AMX0035 in PSP), and its planned …See details»
Amylyx Pharmaceuticals Announces Topline Results From Global …
Mar 8, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced topline results from …See details»
Amylyx Pharmaceuticals: Management Ambitiously Navigates …
Sep 9, 2024 Summary. Amylyx is a "falling knife" that many investors will have either gotten out of or shy away from. But while Amylyx's main drug failed back in March, management has …See details»
Hear stories from the ALS community | Together for ALS
Together for ALS began as a way to share the experiences of people living with ALS and their loved ones. Supported by patient advocacy groups across Europe, including Stichting ALS in …See details»
Amylyx's ALS drug finally scores FDA approval, but that's just the …
Sep 29, 2022 Amylyx isn’t the only one tuned into these issues. The ALS Association is also celebrating the approval. That organization invested $2.2 million of funds raised through …See details»
RELYVRIO - amylyx.com
Oct 2, 2023 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the acceptance of several …See details»
AMX0035 FOR THE TREATMENT OF AMYOTROPHIC LATERAL …
Amylyx AMX0035 Peripheral and Central Nervous Systems Drugs Advisory Committee FINAL Page 11 of 49 1.3 Regulatory and Development History 1.3.1 FDA Interactions – post 30 …See details»
Amylyx: AMX0035 PSP Data In Mid-2025 Just One Program …
Nov 25, 2024 According to the 10-Q SEC Filing, Amylyx Pharmaceuticals had cash, cash equivalents, and marketable securities of $234.4 million as of September 30th, 2024. It took …See details»
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ …
Sep 29, 2022 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug …See details»